Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
纳武利尤单抗联合化疗治疗HER2阴性、既往未接受治疗、不可切除、晚期或复发性胃/胃食管交界处癌患者：ATTRACTION-4随机、双盲、安慰剂对照3期试验的3年随访结果
期刊:Gastric Cancer
影响因子:5.1
doi:10.1007/s10120-024-01535-0
Boku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo
